Ensysce Biosciences Secures $60 Million Capital Commitment From Global Emerging Markets
Ensyce Biosciences notes under the accord, GEM agrees to provide Ensysce with a share subscription facility of up to $60 million for a 36-month term following the public listing of the Company’s common stock.
